CA Patent

CA2582299A1 — Oral pharmaceutical preparation for proton pump antagonists

Assigned to Takeda GmbH · Expires 2006-04-13 · 20y expired

What this patent protects

The invention relates to novel dosage forms for proton pump antagonists.

USPTO Abstract

The invention relates to novel dosage forms for proton pump antagonists.

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

Patent Metadata

Patent number: CA2582299A1
Jurisdiction: CA
Classification: —
Expires: 2006-04-13
Drug substance claim: No
Drug product claim: No
Assignee: Takeda GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.